PRKN and cancer: In the context of tumorigenicity, mutations and deletions of key mitophagy molecular components PINK1 (PARK6) and Parkin (PARK2) genes are frequently observed in various cancer types, including bladder, breast, lung, ovarian, colon, and glioblastoma [130,131,132,133].